An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

Simple item page
dc.contributor.authorFrancis, Jose
dc.contributor.authorBarnes, Karen I.
dc.contributor.authorWorkman, Lesley
dc.contributor.authorKredo, Tamara
dc.contributor.authorVestergaard, Lasse S.
dc.contributor.authorHoglund, Richard M.
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorLamorde, Mohammed
dc.contributor.authorWalimbwa, Stephen I.
dc.contributor.authorChijioke-Nwauche, Ifeyinwa
dc.contributor.authorSutherland, Colin J.
dc.contributor.authorMerry, Concepta
dc.contributor.authorDentia, Paolo
dc.date.accessioned2022-01-12T07:44:44Z
dc.date.available2022-01-12T07:44:44Z
dc.date.issued2020
dc.description.abstractTreating malaria in HIV-coinfected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from 10 studies with 6,100 lumefantrine concentrations from 793 nonpregnant adult participants (41% HIV-malaria-coinfected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers). Lumefantrine exposure increased 3.4-fold with coadministration of lopinavirritonavir- based antiretroviral therapy (ART), while it decreased by 47% with efavirenzbased ART and by 59% in the patients with rifampin-based antituberculosis treatment. Nevirapine- or dolutegravir-based ART and malaria or HIV infection were not associated with significant effects. Monte Carlo simulations showed that those on concomitant efavirenz or rifampin have 49% and 80% probability of day 7 concentrations 200 ng/ml, respectively, a threshold associated with an increased risk of treatment failure. The risk of achieving subtherapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampin, respectively.en_US
dc.identifier.citationCitation Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. 2020. An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrob Agents Chemother 64:e02394-19. https://doi.org/10.1128/AAC.02394-19.en_US
dc.identifier.urihttps://doi.org/10.1128/AAC.02394-19.
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1199
dc.language.isoenen_US
dc.publisherAntimicrobial agents and chemotherapyen_US
dc.subjectUncomplicated malariaen_US
dc.subjectLumefantrineen_US
dc.subjectHuman immunodeficiency virusen_US
dc.subjectDrug-drug interactionsen_US
dc.subjectPopulation pharmacokineticsen_US
dc.titleAn Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatmenten_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment rs.pdf
Size:
576.21 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences